Myelofibrosis surgery: Difference between revisions
Jump to navigation
Jump to search
| Line 8: | Line 8: | ||
==Surgery== | ==Surgery== | ||
===Splenectomy=== | ===Splenectomy=== | ||
Surgery is not the first-line treatment option for patients with myelofibrosis. [[Splenectomy]] is usually reserved for patients with massive splenectomy unresponsive to conservative treatment. | *Surgery is not the first-line treatment option for patients with myelofibrosis. | ||
*[[Splenectomy]] is usually reserved for patients with massive splenectomy unresponsive to conservative treatment.<ref>{{cite book | last = Hoffman | first = Ronald | title = Hematology : basic principles and practice | publisher = Elsevier | location = Philadelphia, PA | year = 2018 | isbn = 9780323357623 }}</ref><ref name="pmid30039550">{{cite journal |vauthors=Tefferi A |title=Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management |journal=Am. J. Hematol. |volume=93 |issue=12 |pages=1551–1560 |date=December 2018 |pmid=30039550 |doi=10.1002/ajh.25230 |url=}}</ref> | |||
*It is associated with postoperative morbidity rate of 15-30% and a mortality rate of 10%. | |||
===Allogeneic stem cell transplantation=== | ===Allogeneic stem cell transplantation=== | ||
Revision as of 01:21, 11 December 2018
|
Myelofibrosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Myelofibrosis surgery On the Web |
|
American Roentgen Ray Society Images of Myelofibrosis surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
Surgery is not the first-line treatment option for patients with myelofibrosis. Splenectomy is usually reserved for patients with massive splenectomy unresponsive to conservative treatment. The only known cure is allogeneic stem cell transplantation, but this approach involves significant risks.
Surgery
Splenectomy
- Surgery is not the first-line treatment option for patients with myelofibrosis.
- Splenectomy is usually reserved for patients with massive splenectomy unresponsive to conservative treatment.[1][2]
- It is associated with postoperative morbidity rate of 15-30% and a mortality rate of 10%.
Allogeneic stem cell transplantation
The only known cure is allogeneic stem cell transplantation, but this approach involves significant risks.[3]
References
- ↑ Hoffman, Ronald (2018). Hematology : basic principles and practice. Philadelphia, PA: Elsevier. ISBN 9780323357623.
- ↑ Tefferi A (December 2018). "Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management". Am. J. Hematol. 93 (12): 1551–1560. doi:10.1002/ajh.25230. PMID 30039550.
- ↑ Cervantes F (2005). "Modern management of myelofibrosis". Br. J. Haematol. 128 (5): 583–92. doi:10.1111/j.1365-2141.2004.05301.x. PMID 15725078. Unknown parameter
|month=ignored (help)